Clinical Trials Logo

Sickle Cell Anemia clinical trials

View clinical trials related to Sickle Cell Anemia.

Filter by:

NCT ID: NCT00736060 Completed - Sickle Cell Anemia Clinical Trials

Clinical and Laboratory Characteristics of Sickle Cell Anemia Patients Admitted With Fever

Start date: May 2008
Phase: N/A
Study type: Observational

This study will summarized the clinical and laboratory data and the outcome of all the patients suffering from Sickle Cell Anemia (Including Sickle cell thalassemia) admitted to the pediatric ward.

NCT ID: NCT00735540 Completed - Clinical trials for Chronic Renal Failure

Clinical Diagnosis of Teenagers Admitted to Pediatric Departments

Start date: May 2008
Phase: N/A
Study type: Observational

This study intends to analyze the clinical characteristics of teenagers admitted to pediatric wards due to organic illness and non organic diagnosis, including patients suffering from chronic diseases and comorbidity.

NCT ID: NCT00735488 Completed - Sickle Cell Anemia Clinical Trials

Sickle Cell Anemia Screening and Prevention in Northern Israel

Start date: May 2008
Phase: N/A
Study type: Observational

Since 1987, a screening for β Thalassemia in pregnant women is carried on in northern Israel, and from 1999 all the samples were tested also for Hgb S, Hgb C, Hgb D, Hgb O Arab and others. In this study, the investigators intend to summarize the results of this preventive program aiming to detect couples at risk for having offspring with Thalassemia or SCA, the compliance regard to genetic counseling and prenatal diagnosis and the incidence of new affected babies born.

NCT ID: NCT00672789 Completed - Sickle Cell Anemia Clinical Trials

Adherence to Hydroxyurea in Children With Sickle Cell Anemia

Start date: April 2008
Phase: N/A
Study type: Interventional

Medication non-adherence is a true public health problem. Despite advancements in the molecular understanding of disease and improvements in therapy, patient health outcomes will not improve unless patients take prescribed medications regularly. Decreasing the gap between efficacious and effective therapy for patients with SCD is an essential research agenda. Hydroxyurea has been shown to be safe and efficacious in children and infants. However, the effectiveness of the prophylaxis depends on adherence to the recommended regimen. Medication adherence in SCD has previously been found to be sub-optimal in patients taking penicillin, desferoxamine, and pain medication. Adherence to HU has been studied to some extent in children with SCD. Based on estimates of adherence in other chronic illness we expect approximately 50% of patients to be >80% adherent with their HU administration. There is no gold standard for improving adherence to treatment. There have been a few attempts in the SCD population to improve adherence. These include a day camp to promote education about desferoxamine and peer support, a combination of a slide-show about SCD and it complications, weekly phone calls by the clinic social worker and a calendar, and a seven-phase educational program. Given the striking improvements in the peripheral blood smear findings of patients with SCD on HU therapy, with reduction in the numbers of sickled cells, we hypothesize that viewing the peripheral blood smear of patients with poor adherence to HU compared to a blood smear of someone on HU can be used to improve adherence in non-adherent patients. We will conduct a randomized trial between the intervention of regularly showing children and their parents the peripheral blood smear and standard care, including reminders of the importance of compliance and review of complete blood count parameters, including WBC, MCV, and Hgb concentration. The outcome measures will be increase in hemoglobin concentration and %HbF and increase in perceived QOL. QOL will be measured with age-appropriate and parent/proxy PedsQL™. Medication adherence will also be monitored throughout the study with pharmacy prescription refills, physician assessment, and self-report via a visual analogue scale. Adherence estimates, hemoglobin concentration, %HbF and QOL will be measured at baseline, 3 months and 6 months.

NCT ID: NCT00669305 Completed - Sickle Cell Anemia Clinical Trials

Bone Marrow for Hemoglobinopathy Research

Start date: May 15, 2008
Phase:
Study type: Observational

Human participants affected with sickle cell disease or thalassemia will donate bone marrow for use in experimental laboratory models to study potential new treatments. This is an observational study using bone marrow from human participants. The investigators will use sickle cell and thalassemia mouse models to observe and evaluate the possibility of correcting these disorders through genetic alterations or drug treatment.

NCT ID: NCT00618644 Withdrawn - Sickle Cell Anemia Clinical Trials

Ranibizumab for Neovascularization in Sickle Cell Retinopathy

Start date: January 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the ocular and non-ocular safety of a single dose of ranibizumab in treating neovascularization secondary to sickle cell retinopathy.

NCT ID: NCT00586209 Terminated - Sickle Cell Anemia Clinical Trials

L-Glutamine Therapy for Sickle Cell Anemia

Start date: February 6, 2004
Phase: Phase 2
Study type: Interventional

The primary purpose is to evaluate the effect of L-glutamine therapy on exercise endurance and breath by breath exercise response of sickle cell anemia patients The secondary purpose is to assess the effect of L-glutamine on incidence of painful crises; level of chronic pain, and amount of daily requirement for narcotics.

NCT ID: NCT00578435 Completed - Sickle Cell Anemia Clinical Trials

Allogeneic Bone Marrow Transplantation for the Treatment of Genetic Disorders of Erythropoiesis

Start date: January 1994
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine and confirm the role of bone marrow transplantation in the treatment of disorders of the red cell and hemoglobin including sickle cell anemia, thalassemia and diamond blackfan anemia.

NCT ID: NCT00542230 Recruiting - Sickle Cell Disease Clinical Trials

Blood Sampling for Research Related to Sickle Cell Disease

Start date: November 7, 2007
Phase:
Study type: Observational

This study will collect representative blood samples from healthy children and adults and from children and adults who have unique red blood cell features that are related to sickle cell disease. Sickle cell disease is a blood disease that limits the ability of red blood cells to carry oxygen throughout the body. The purpose of the study is to collect a variety of blood samples that may then be used to investigate advances and potential new drug treatments for sickle cell disease. Volunteers must be at least 18 years of old. Samples will be taken both from healthy volunteers and from volunteers who have unique red blood cell features that are related to sickle cell disease. Candidates will be screened with a medical history. During the study, participants will undergo a one- to two-hour outpatient procedure at the National Institutes of Health Clinical Center. Once researchers have explained the study and obtained the participant s consent, participants will donate 8 cc (approximately 2 teaspoons) of blood. Because repeat testing helps researchers validate study findings, participants who have the unique red blood cell features mentioned above may also be asked if they are willing to return and donate another 2 cc to 8 cc of blood for additional studies. The amount of blood drawn will not exceed 50 ml with any eight-week period for adults or 7 cc within any six-week period for children....

NCT ID: NCT00538564 Withdrawn - Sickle Cell Anemia Clinical Trials

Tadalafil for Treatment of Priapism in Men With Sickle Cell Anemia

Start date: November 2006
Phase: Phase 2
Study type: Interventional

This research is being done to compare the effect of tadalafil with placebo (an inactive substance that looks like the study drug, but should have no effect) on the frequency of recurrent priapism (prolonged erection, unassociated with sexual interest or desire) and the nature of sexual experiences in male patients with sickle cell disease.